ACH
Next earnings: Aug 10, 2026
Signal
Bearish Setup2
Price
1
Move-4.28%Selling pressure
Volume
1
Volume0.9× avgNormal activity
Technical
1
RSIRSI 43Momentum negative
PRICE
Prev Close
3.04
Open
2.97
Day Range2.90 – 3.18
2.90
3.18
52W Range1.84 – 9.55
1.84
9.55
14% of range
VOLUME & SIZE
Avg Volume
879.5K
FUNDAMENTALS
P/E Ratio
-2.1x
Not profitable
EPS (TTM)
Div Yield
No dividend
Quick Read
TrendInsufficient MA data
Momentum
NEUTRAL
rev -59% · 41% gross margin
Valuation
FAIR
P/E not available
Health
WEAK
CR 0.5 (low) · FCF negative
Lean Bearish
Key MetricsTTM
Market Cap$222.86M
Revenue TTM$2.72B
Net Income TTM-$1.08B
Free Cash Flow-$179.80M
Gross Margin41.3%
Net Margin-39.8%
Operating Margin3.5%
Return on Equity264.5%
Return on Assets-44.8%
Debt / Equity-4.67
Current Ratio0.49
EPS TTM$-14.11
Alpha SignalsFull Analysis →
What Moves This Stock

Gross margin trends and ability to maintain pricing power against larger competitors like McKesson, AmerisourceBergen, and Cardinal Health

Working capital management and cash conversion cycle - critical given 0.86 current ratio and negative free cash flow

Customer concentration risk and contract renewals with major hospital systems or pharmacy chains

Debt refinancing ability and covenant compliance given negative equity position and distressed balance sheet

Macro Sensitivity
Economic Cycle

low-to-moderate - Healthcare spending is relatively non-discretionary and continues through economic cycles, but elective procedures and certain specialty drug volumes can decline during recessions. Hospital utilization rates and patient volumes affect distributor throughput. The company's financial distress makes it more vulnerable to any demand softness that pressures already-thin margins.

Interest Rates

High sensitivity given distressed financial position. Rising interest rates increase financing costs on working capital lines and any debt refinancing, which is particularly damaging given negative operating margins. Higher rates also reduce valuation multiples for unprofitable companies and make restructuring more expensive. The negative equity position suggests significant debt burden relative to asset base.

Key Risks

Industry consolidation among larger distributors (McKesson, AmerisourceBergen, Cardinal Health control ~90% of market) creates pricing pressure and limits growth opportunities for smaller players

Pharmaceutical pricing reform and potential government intervention in drug pricing could compress distributor margins further

Direct-to-provider distribution models by manufacturers (bypassing distributors) and vertical integration by pharmacy benefit managers threaten traditional distribution economics

Investor Profile

distressed/special situations - The severe financial deterioration, negative equity, and 67% stock decline attract distressed debt investors, bankruptcy specialists, and high-risk equity traders betting on restructuring outcomes rather than fundamental business performance. Traditional value or growth investors would avoid given lack of profitability and balance sheet impairment. Extremely high risk/reward profile suitable only for sophisticated investors with distressed credit expertise.

Watch on Earnings
Quarterly gross margin percentage and sequential trends - any further compression signals existential threatCash flow from operations and free cash flow generation - must turn positive to avoid liquidity crisisCurrent ratio and working capital levels - early warning indicator of potential bankruptcyDebt covenant compliance status and credit facility availability
Health Radar
2 strong1 watch3 concern
46/100
Liquidity
0.49Concern
Leverage
-4.67Strong
Coverage
0.7xConcern
ROE
264.5%Strong
ROIC
4.9%Concern
Cash
$282MWatch
ANALYST COVERAGE13 analysts
HOLD
+80.4%upside to target
L $4.50
Med $5.25consensus
H $6.00
Buy
323%
Hold
862%
Sell
215%
3 Buy (23%)8 Hold (62%)2 Sell (15%)
Full report →
Stock Health
Composite Score
1 of 5 signals bullish
3/10
Technicals
RSI RangeRSI 43 — Bearish momentum
Volume
Volume FlowDistribution — institutional selling
Fundamentals
Last EarningsBeat estimates
Analyst ConsensusHold
~
LiquidityCurrent Ratio 0.49 — liquidity risk
Upcoming Events
EEarnings ReportMay 18, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 89 days
PDividend PaymentSep 9, 2026
In 115 days
Technicals
Technical SetupBULLISH
Technicals →

Trend

UptrendGolden Cross · 50D leads 200D by 300.0%

+69.2% vs SMA 50 · +576.8% vs SMA 200

Momentum

RSI43.1
Momentum fading
MACD+0.10
Above zero — bullish momentum · compressing
Market Position
Price Levels
52W High
$9.55+228.2%
Current
$2.91
52W Low
$1.84-36.8%
EMA 50
$1.77-39.1%
EMA 200
$0.4559-84.3%
52-Week RangeNear 52-week low
$1.8414th %ile$9.55
Squeeze SetupVolume-based
Distribution Pressure

Heavy distribution on elevated volume — institutions appear to be exiting. Squeeze setups unlikely while selling pressure persists.

20-Day Money Flow
Acc days:2
Dist days:3
Edge:+1 dist
Volume Context
Avg Vol (50D)865K
Recent Vol (5D)
1.7M+93%

Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.

Earnings & Analysts

ANALYST ESTIMATES

Consensus of 4 analysts
Analyst revisions:EPS↑ Revised UpRevenue↑ Revised Up

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2024
$10.7B
$10.5B$10.9B
$1.50
±3%
Moderate3
FY2025
$2.8B
$2.7B$2.8B
-74.1%$1.01-32.2%
±4%
Moderate4
FY2026(current)
$2.6B
$2.5B$2.6B
-6.8%$0.45-55.5%
±49%
Moderate4
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryACH
Last 8Q
+8.3%avg beat
Beat 6 of 8 quartersMissed 2 Estimates falling
+9%
Q3'24
+5%
Q4'24
+4%
Q1'25
+15%
Q2'25
-4%
Q3'25
+9%
Q4'25
-5%
Q1'26
+33%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Analyst Activity
All ratings →
No recent activity
UBSBuy → Neutral
Nov 3
DOWNGRADE
UBSBuy
Nov 3
DOWNGRADE
CitigroupNeutral → Buy
Jul 19
UPGRADE
Insider Activity
SEC Filings →
6 Buys/0 SellsNet Buying
Coliseum Capital Ma…10 Percent Own…
$2.6M
Aug 14
BUY
Coliseum Capital Ma…10 Percent Own…
$1.8M
Aug 13
BUY
Coliseum Capital Ma…10 Percent Own…
$3.7M
Aug 12
BUY
Coliseum Capital Ma…10 Percent Own…
$575K
Apr 10
BUY
Coliseum Capital Ma…10 Percent Own…
$1.7M
Apr 9
BUY
Coliseum Capital Ma…10 Percent Own…
$836K
Apr 8
BUY
Financials

INSTITUTIONAL OWNERSHIP

1
PARAMETRIC PORTFOLIO ASSOCIATES LLC
224K
2
Dixon Hughes Goodman Wealth Advisors LLC
69
3
Marshall Wace North America L.P.
45K
4
OLD MISSION CAPITAL, LLC
222K
5
Aperio Group, LLC
86K
6
LADENBURG THALMANN FINANCIAL SERVICES INC.
410
7
Advisor Group, Inc.
152
8
Financial Gravity Companies, Inc.
8
News & Activity

ACH News

About

No description available.

Industry
Alumina Refining and Primary Aluminum Production
Country
China (Mainland)
Perry A. BernocchiExecutive VP & COO
Edward A. PesickaPresident, Chief Executive Officer & Director
Heath H. GallowayExecutive Vice President, General Counsel & Corporate Secretary
PeersHealth Care(7 companies)
Screen sector →
SymbolPriceDay %Mkt CapP/ERev GrwMarginELO
ACH
$2.91+0.00%$223M-3984.9%1500
$66.13-5.07%$13.0B+12626.1%-14525.8%1500
$94.92-3.79%$12.6B+3288.2%-4239.0%1500
$523.69-3.00%$12.1B+43205.3%-3008.0%1500
$227.72-1.96%$11.7B+6554.5%-2868.8%1500
$57.90-0.86%$11.2B50.3+1459.3%147.7%1500
$76.67-3.79%$10.8B+2325815.3%-19.7%1500
Sector avg-2.64%50.3+398824.8%-4071.2%1500